KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Shares Issued (2018 - 2025)

Aquestive Therapeutics has reported Shares Issued over the past 8 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Shares Issued at $1.2 million for Q4 2025, up 73.79% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (up 73.5% YoY), and the annual figure for FY2025 was $1.3 million, up 73.5%.
  • Shares Issued for Q4 2025 was $1.2 million at Aquestive Therapeutics, up from $43000.0 in the prior quarter.
  • Over the last five years, Shares Issued for AQST hit a ceiling of $9.9 million in Q1 2021 and a floor of -$24.4 million in Q4 2021.
  • Median Shares Issued over the past 5 years was $702000.0 (2024), compared with a mean of $150666.7.
  • Peak annual rise in Shares Issued hit 9717.74% in 2021, while the deepest fall reached 39266.13% in 2021.
  • Aquestive Therapeutics' Shares Issued stood at -$24.4 million in 2021, then soared by 84.55% to -$3.8 million in 2022, then skyrocketed by 101.03% to $39000.0 in 2023, then surged by 1700.0% to $702000.0 in 2024, then surged by 73.79% to $1.2 million in 2025.
  • The last three reported values for Shares Issued were $1.2 million (Q4 2025), $43000.0 (Q3 2025), and $7000.0 (Q2 2025) per Business Quant data.